-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AOC-1044 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1044 in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1044 in Duchenne Muscular Dystrophy Drug Details: AOC-1044 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bidridistrogene Xeboparvovec in Limb-Girdle Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bidridistrogene Xeboparvovec in Limb-Girdle Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bidridistrogene Xeboparvovec in Limb-Girdle Muscular Dystrophy Drug Details: bidridistrogene xeboparvovec...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Becker Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Becker Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Becker Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Spinal Muscular Atrophy (SMA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Drugs In Development, 2023’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Limb-Girdle Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Limb-Girdle Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Limb-Girdle Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Limb-Girdle Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Facioscapulohumeral Muscular Dystrophy (FSHD) - Drugs In Development, 2023’, provides an overview of the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Facioscapulohumeral Muscular Dystrophy (FSHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Duchenne Muscular Dystrophy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Duchenne Muscular Dystrophy Clinical Trial Report Overview A total of 390 Duchenne muscular dystrophy clinical trials were conducted as of January 2024. The Duchenne Muscular Dystrophy clinical trial report provides a comprehensive understanding of the Duchenne muscular dystrophy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...